Top

Published in:

01-09-2014

RANK-mediated signaling network and cancer metastasis

Authors: Gina Chia-Yi Chu, Leland W. K. Chung

Published in: Cancer and Metastasis Reviews | Issue 2-3/2014

Abstract

Cancer metastasis is highly inefficient and complex. Common features of metastatic cancer cells have been observed using cancer cell lines and genetically reconstituted mouse and human tumor xenograft models. These include cancer cell interaction with the tumor microenvironment and the ability of cancer cells to sense extracellular stimuli and adapt to adverse growth conditions. This review summarizes the coordinated response of cancer cells to soluble growth factors, such as RANKL, by a unique feed forward mechanism employing coordinated upregulation of RANKL and c-Met with downregulation of androgen receptor. The RANK-mediated signal network was found to drive epithelial to mesenchymal transition in prostate cancer cells, promote osteomimicry and the ability of prostate cancer cells to assume stem cell and neuroendocrine phenotypes, and confer the ability of prostate cancer cells to home to bone. Prostate cancer cells with activated RANK-mediated signal network were observed to recruit and even transform the non-tumorigenic prostate cancer cells to participate in bone and soft tissue colonization. The coordinated regulation of cancer cell invasion and metastasis by the feed forward mechanism involving RANKL, c-Met, transcription factors, and VEGF-neuropilin could offer new therapeutic opportunities to target prostate cancer bone and soft tissue metastases.

Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002). Dissemination and growth of cancer cells in metastatic sites. Nature Reviews Cancer, 2(8), 563–572. doi:10.1038/nrc865.PubMed

Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nature Reviews Cancer, 3(6), 453–458. doi:10.1038/nrc1098.PubMed

Kang, Y., & Massague, J. (2004). Epithelial-mesenchymal transitions: twist in development and metastasis. Cell, 118(3), 277–279. doi:10.1016/j.cell.2004.07.011.PubMed

Alderton, G. K. (2012). Metastasis: Converging targets. Naturforschende Review Cancer, 12(12), 793. doi:10.1038/nrc3411.

Hardy, K. M., Kirschmann, D. A., Seftor, E. A., Margaryan, N. V., Postovit, L. M., Strizzi, L., et al. (2010). Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Research, 70(24), 10340–10350. doi:10.1158/0008-5472.CAN-10-0705.PubMedCentralPubMed

Cui, H., Grosso, S., Schelter, F., Mari, B., & Kruger, A. (2012). On the Pro-Metastatic Stress Response to Cancer Therapies: Evidence for a Positive Co-Operation between TIMP-1, HIF-1alpha, and miR-210. Frontiers in Pharmacology, 3, 134. doi:10.3389/fphar.2012.00134.PubMedCentralPubMed

Qi, Y., Li, R. M., Kong, F. M., Li, H., Yu, J. P., & Ren, X. B. (2012). How do tumor stem cells actively escape from host immunosurveillance? Biochemical and Biophysical Research Communications, 420(4), 699–703. doi:10.1016/j.bbrc.2012.03.086.PubMed

Mitchell, M. J., & King, M. R. (2013). Computational and experimental models of cancer cell response to fluid shear stress. Frontiers Oncologica, 3, 44. doi:10.3389/fonc.2013.00044.

Di Vizio, D., Morello, M., Dudley, A. C., Schow, P. W., Adam, R. M., Morley, S., et al. (2012). Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. The American Journal of Pathology, 181(5), 1573–1584. doi:10.1016/j.ajpath.2012.07.030.PubMedCentralPubMed

10.

Odero-Marah, V. A., Wang, R., Chu, G., Zayzafoon, M., Xu, J., Shi, C., et al. (2008). Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Research, 18(8), 858–870. doi:10.1038/cr.2008.84.PubMed

11.

Zhau, H. E., Odero-Marah, V., Lue, H. W., Nomura, T., Wang, R., Chu, G., et al. (2008). Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clinical and Experimental Metastasis, 25(6), 601–610. doi:10.1007/s10585-008-9183-1.PubMedCentralPubMed

12.

Zhau, H. E., Li, Q., & Chung, L. W. (2013). Interracial differences in prostate cancer progression among patients from the United States, China and Japan. Asian Journal of Andrology. doi:10.1038/aja.2013.86.PubMedCentralPubMed

13.

Hu, P. Z., Chung, L. W., Berel, D., Frierson, H. F., Yang, H., Liu, C. Y., et al. (2013). Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study. PLoS One., 8, e73081.PubMedCentralPubMed

14.

Roodman, G. D. (2012). Genes associate with abnormal bone cell activity in bone metastasis. Cancer and Metastasis Reviews, 31(3–4), 569–578. doi:10.1007/s10555-012-9372-x.PubMed

15.

Joshi, P. A., Jackson, H. W., Beristain, A. G., Di Grappa, M. A., Mote, P. A., Clarke, C. L., et al. (2010). Progesterone induces adult mammary stem cell expansion. Nature, 465(7299), 803–807. doi:10.1038/nature09091.PubMed

16.

Li, X., Ominsky, M. S., Stolina, M., Warmington, K. S., Geng, Z., Niu, Q. T., et al. (2009). Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone, 45(4), 669–676. doi:10.1016/j.bone.2009.06.011.PubMed

17.

Sanbe, T., Tomofuji, T., Ekuni, D., Azuma, T., Irie, K., Tamaki, N., et al. (2009). Vitamin C intake inhibits serum lipid peroxidation and osteoclast differentiation on alveolar bone in rats fed on a high-cholesterol diet. Archives of Oral Biology, 54(3), 235–240. doi:10.1016/j.archoralbio.2008.11.001.PubMed

18.

Roodman, G. D., & Dougall, W. C. (2008). RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treatment Reviews, 34(1), 92–101. doi:10.1016/j.ctrv.2007.09.002.PubMed

19.

Smith, M. R., Saad, F., Coleman, R., Shore, N., Fizazi, K., Tombal, B., et al. (2012). Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet, 379(9810), 39–46. doi:10.1016/S0140-6736(11)61226-9.PubMedCentralPubMed

20.

Dougall, W. C. (2012). Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clinical Cancer Research, 18(2), 326–335. doi:10.1158/1078-0432.CCR-10-2507.PubMed

21.

Chu, C. Y. (2011). The role of RANKL in prostate cancer progression and bone metastasis. Ph.D Thesis., Georgia State University,

22.

Hu, P., Chu, G. C., Zhu, G., Yang, H., Luthringer, D., Prins, G., et al. (2011). Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. PLoS One, 6(12), e28670. doi:10.1371/journal.pone.0028670.PubMedCentralPubMed

23.

Cox, R. F., Jenkinson, A., Pohl, K., O’Brien, F. J., & Morgan, M. P. (2012). Osteomimicry of mammary adenocarcinoma cells in vitro; increased expression of bone matrix proteins and proliferation within a 3D collagen environment. PLoS One, 7(7), e41679. doi:10.1371/journal.pone.0041679.PubMedCentralPubMed

24.

Koeneman, K. S., Yeung, F., & Chung, L. W. (1999). Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate, 39(4), 246–261.PubMed

25.

Knerr, K., Ackermann, K., Neidhart, T., & Pyerin, W. (2004). Bone metastasis: Osteoblasts affect growth and adhesion regulons in prostate tumor cells and provoke osteomimicry. International Journal of Cancer, 111(1), 152–159. doi:10.1002/ijc.20223.

26.

Rucci, N., & Teti, A. (2010). Osteomimicry: how tumor cells try to deceive the bone. Frontiers in Bioscience (Scholar Edition), 2, 907–915.

27.

Kavitha, C. V., Deep, G., Gangar, S. C., Jain, A. K., Agarwal, C., & Agarwal, R. (2012). Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-kappaB, and AP-1 Activation in RAW264.7 cells. Molecular Carcinogenesis. doi:10.1002/mc.21959.PubMed

28.

Graham, T. R., Agrawal, K. C., & Abdel-Mageed, A. B. (2010). Independent and cooperative roles of tumor necrosis factor-alpha, nuclear factor-kappaB, and bone morphogenetic protein-2 in regulation of metastasis and osteomimicry of prostate cancer cells and differentiation and mineralization of MC3T3-E1 osteoblast-like cells. Cancer Science, 101(1), 103–111. doi:10.1111/j.1349-7006.2009.01356.x.PubMedCentralPubMed

29.

Yuen, H. F., Kwok, W. K., Chan, K. K., Chua, C. W., Chan, Y. P., Chu, Y. Y., et al. (2008). TWIST modulates prostate cancer cell-mediated bone cell activity and is upregulated by osteogenic induction. Carcinogenesis, 29(8), 1509–1518. doi:10.1093/carcin/bgn105.PubMed

30.

Glait-Santar, C., & Benayahu, D. (2012). Regulation of SVEP1 gene expression by 17beta-estradiol and TNFalpha in pre-osteoblastic and mammary adenocarcinoma cells. The Journal of Steroid Biochemistry and Molecular Biology, 130(1–2), 36–44. doi:10.1016/j.jsbmb.2011.12.015.PubMed

31.

Josson, S., Nomura, T., Lin, J. T., Huang, W. C., Wu, D., Zhau, H. E., et al. (2011). beta2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Research, 71(7), 2600–2610. doi:10.1158/0008-5472.CAN-10-3382.PubMedCentralPubMed

32.

Huang, W. C., Havel, J. J., Zhau, H. E., Qian, W. P., Lue, H. W., Chu, C. Y., et al. (2008). Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells. Clinical Cancer Research, 14(17), 5341–5347. doi:10.1158/1078-0432.CCR-08-0793.PubMedCentralPubMed

33.

Huang, W. C., Wu, D., Xie, Z., Zhau, H. E., Nomura, T., Zayzafoon, M., et al. (2006). beta2-microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Research, 66(18), 9108–9116. doi:10.1158/0008-5472.CAN-06-1996.PubMed

34.

Huang, W. C., Zhau, H. E., & Chung, L. W. (2010). Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. The Journal of Biological Chemistry, 285(11), 7947–7956. doi:10.1074/jbc.M109.092759.PubMedCentralPubMed

35.

Nomura, T., Huang, W. C., Seo, S., Zhau, H. E., Mimata, H., & Chung, L. W. (2007). Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. The Journal of Urology, 178(1), 292–300. doi:10.1016/j.juro.2007.03.007.PubMed

36.

Nomura, T., Huang, W. C., Zhau, H. E., Josson, S., Mimata, H., & Chung, L. W. (2013). beta2-Microglobulin-mediated signaling as a target for cancer therapy. Anticancer Agents Med Chem. doi:10.2174/18715206113139990092

37.

Nomura, T., Huang, W. C., Zhau, H. E., Wu, D., Xie, Z., Mimata, H., et al. (2006). Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clinical Cancer Research, 12(24), 7294–7305. doi:10.1158/1078-0432.CCR-06-2060.PubMed

38.

Lue, H. W., Yang, X., Wang, R., Qian, W., Xu, R. Z., Lyles, R., et al. (2011). LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling. PLoS One, 6(11), e27720. doi:10.1371/journal.pone.0027720.PubMedCentralPubMed

39.

Gross, M., Top, I., Laux, I., Katz, J., Curran, J., Tindell, C., et al. (2007). Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. Clinical Cancer Research, 13(7), 1979–1986. doi:10.1158/1078-0432.CCR-06-1156.PubMed

40.

Michaelson, J. (1983). Genetics of beta-2 microglobulin in the mouse. Immunogenetics, 17(3), 219–260.PubMed

41.

Solheim, J. C. (1999). Class I MHC molecules: assembly and antigen presentation. Immunological Reviews, 172, 11–19.PubMed

42.

Josson, S., Matsuoka, Y., Gururajan, M., Nomura, T., Huang, W. C., Yang, X., et al. (2013). Inhibition of beta2-Microglobulin/Hemochromatosis Enhances Radiation Sensitivity by Induction of Iron Overload in Prostate Cancer Cells. PLoS One, 8(7), e68366. doi:10.1371/journal.pone.0068366.PubMedCentralPubMed

43.

Josson, S., Matsuoka, Y., Chung, L. W., Zhau, H. E., & Wang, R. (2010). Tumor-stroma co-evolution in prostate cancer progression and metastasis. Seminars in Cell and Developmental Biology, 21(1), 26–32. doi:10.1016/j.semcdb.2009.11.016.PubMedCentralPubMed

44.

Yang, J., Qian, J., Wezeman, M., Wang, S., Lin, P., Wang, M., et al. (2006). Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell, 10(4), 295–307. doi:10.1016/j.ccr.2006.08.025.PubMed

45.

Yang, J., Zhang, X., Wang, J., Qian, J., Zhang, L., Wang, M., et al. (2007). Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood, 110(8), 3028–3035. doi:10.1182/blood-2007-06-094417.PubMedCentralPubMed

46.

Guise, T. A., Kozlow, W. M., Heras-Herzig, A., Padalecki, S. S., Yin, J. J., & Chirgwin, J. M. (2005). Molecular mechanisms of breast cancer metastases to bone. Clinical of Breast Cancer, 5(2), S46–S53.

47.

Atwood, S. X., Li, M., Lee, A., Tang, J. Y., & Oro, A. E. (2013). GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas. Nature, 494(7438), 484–488. doi:10.1038/nature11889.PubMedCentralPubMed

48.

Bershteyn, M., Atwood, S. X., Woo, W. M., Li, M., & Oro, A. E. (2010). MIM and cortactin antagonism regulates ciliogenesis and hedgehog signaling. Developmental Cell, 19(2), 270–283. doi:10.1016/j.devcel.2010.07.009.PubMedCentralPubMed

49.

Dunkel, Y., Ong, A., Notani, D., Mittal, Y., Lam, M., Mi, X., et al. (2012). STAT3 protein up-regulates Galpha-interacting vesicle-associated protein (GIV)/Girdin expression, and GIV enhances STAT3 activation in a positive feedback loop during wound healing and tumor invasion/metastasis. The Journal of Biological Chemistry, 287(50), 41667–41683. doi:10.1074/jbc.M112.390781.PubMedCentralPubMed

50.

Hassan, M. Q., Maeda, Y., Taipaleenmaki, H., Zhang, W., Jafferji, M., Gordon, J. A., et al. (2012). miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. The Journal of Biological Chemistry, 287(50), 42084–42092. doi:10.1074/jbc.M112.377515.PubMedCentralPubMed

51.

Kinoshita, T., Hanazawa, T., Nohata, N., Kikkawa, N., Enokida, H., Yoshino, H., et al. (2012). Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget, 3(11), 1386–1400.PubMedCentralPubMed

52.

Tatarano, S., Chiyomaru, T., Kawakami, K., Enokida, H., Yoshino, H., Hidaka, H., et al. (2011). miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. International Journal of Oncology, 39(1), 13–21. doi:10.3892/ijo.2011.1012.PubMed

53.

Uesugi, A., Kozaki, K., Tsuruta, T., Furuta, M., Morita, K., Imoto, I., et al. (2011). The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Research, 71(17), 5765–5778. doi:10.1158/0008-5472.CAN-11-0368.PubMed

54.

Yamamoto, N., Kinoshita, T., Nohata, N., Itesako, T., Yoshino, H., Enokida, H., et al. (2013). Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion by targeting focal adhesion pathways in cervical squamous cell carcinoma. International Journal of Oncology, 42(5), 1523–1532. doi:10.3892/ijo.2013.1851.PubMedCentralPubMed

55.

Yamasaki, T., Seki, N., Yoshino, H., Itesako, T., Hidaka, H., Yamada, Y., et al. (2013). MicroRNA-218 Inhibits Cell Migration and Invasion in Renal Cell Carcinoma through Targeting Caveolin-2 Involved in Focal Adhesion Pathway. The Journal of Urology, 190(3), 1059–1068. doi:10.1016/j.juro.2013.02.089.PubMed

56.

Tang, Y., Kesavan, P., Nakada, M. T., & Yan, L. (2004). Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Molecular Cancer Research, 2(2), 73–80.PubMed

57.

Tang, Y., Nakada, M. T., Kesavan, P., McCabe, F., Millar, H., Rafferty, P., et al. (2005). Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Research, 65(8), 3193–3199. doi:10.1158/0008-5472.CAN-04-3605.PubMed

58.

Tang, Y., Nakada, M. T., Rafferty, P., Laraio, J., McCabe, F. L., Millar, H., et al. (2006). Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Molecular Cancer Research, 4(6), 371–377. doi:10.1158/1541-7786.MCR-06-0042.PubMed

59.

Marioni, G., Blandamura, S., Giacomelli, L., Calgaro, N., Segato, P., Leo, G., et al. (2005). Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology, 46(5), 576–582. doi:10.1111/j.1365-2559.2005.02141.x.PubMed

60.

Chu, G. C.-Y., Zhau, H. E., Wang, R. Rogatko, A., Feng, X., Zayzafoon, M., Liu, Y., Farach-Carson, M. C., You, S., Kim, J., Freeman, M. R., Chung, L. W. (2013). RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr Relat Cancer (in press).

61.

Chu, G. C.-Y., Zhau, H. E., Wang, R. Rogatko, A., Feng, X., Zayzafoon, M., Liu, Y., Farach-Carson, M. C., Chung, L. W. (2013). Autocrine/paracrine RANKL-RANK signaling promotes cancer bone metastasis and establishes premetastatic niche recruiting bystander cancer cells to participate in the metastatic process. Washington, DC: American Association for Cancer Research.

62.

Kaur, B., Khwaja, F. W., Severson, E. A., Matheny, S. L., Brat, D. J., & Van Meir, E. G. (2005). Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-Oncology, 7(2), 134–153. doi:10.1215/S1152851704001115.PubMedCentralPubMed

63.

Kimbro, K. S., & Simons, J. W. (2006). Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocrine-Related Cancer, 13(3), 739–749. doi:10.1677/erc.1.00728.PubMed

64.

Powis, G., & Kirkpatrick, L. (2004). Hypoxia inducible factor-1alpha as a cancer drug target. Molecular Cancer Therapeutics, 3(5), 647–654.PubMed

65.

Smith, B. N., & Odero-Marah, V. A. (2012). The role of Snail in prostate cancer. Cell Adhesion & Migration, 6(5), 433–441. doi:10.4161/cam.21687.

66.

Jiang, J., Tang, Y. L., & Liang, X. H. (2011). EMT: a new vision of hypoxia promoting cancer progression. Cancer Biology and Therapy, 11(8), 714–723.PubMed

67.

Konisti, S., Kiriakidis, S., & Paleolog, E. M. (2012). Hypoxia–a key regulator of angiogenesis and inflammation in rheumatoid arthritis. Nature Reviews. Rheumatology, 8(3), 153–162. doi:10.1038/nrrheum.2011.205.PubMed

68.

McNamee, E. N., Korns Johnson, D., Homann, D., & Clambey, E. T. (2013). Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function. Immunologic Research, 55(1–3), 58–70. doi:10.1007/s12026-012-8349-8.PubMedCentralPubMed

69.

Shay, J. E., & Celeste Simon, M. (2012). Hypoxia-inducible factors: crosstalk between inflammation and metabolism. Seminars in Cell and Developmental Biology, 23(4), 389–394. doi:10.1016/j.semcdb.2012.04.004.PubMed

70.

Tomita, S., Kihira, Y., Imanishi, M., Fukuhara, Y., Imamura, Y., Ishizawa, K., et al. (2011). Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery:inflammatory responses of hypoxia-inducible factor 1alpha (HIF-1alpha) in T cells observed in development of vascular remodeling. Journal of Pharmacological Sciences, 115(4), 433–439.PubMed

71.

Brabletz, S., & Brabletz, T. (2010). The ZEB/miR-200 feedback loop–a motor of cellular plasticity in development and cancer? EMBO Reports, 11(9), 670–677. doi:10.1038/embor.2010.117.PubMedCentralPubMed

72.

Guo, L., Chen, C., Shi, M., Wang, F., Chen, X., Diao, D., et al. (2013). Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition. Oncogene. doi:10.1038/onc.2012.573.

73.

Chung, L. W. (1995). The role of stromal-epithelial interaction in normal and malignant growth. Cancer Surveys, 23, 33–42.PubMed

74.

Cunha, G. R. (1994). Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer, 74(3 Suppl), 1030–1044.PubMed

75.

Donjacour, A. A., & Cunha, G. R. (1991). Stromal regulation of epithelial function. Cancer Treatment and Research, 53, 335–364.PubMed

76.

Roberts, A. B., & Sporn, M. B. (1987). Transforming growth factor-beta: potential common mechanisms mediating its effects on embryogenesis, inflammation-repair, and carcinogenesis. International Journal of Radiation Applications and Instrumentation. Part B, 14(4), 435–439.

77.

Sakakura, T. (1991). New aspects of stroma-parenchyma relations in mammary gland differentiation. International Review of Cytology, 125, 165–202.PubMed

78.

Chung, L. W., Huang, W. C., Sung, S. Y., Wu, D., Odero-Marah, V., Nomura, T., et al. (2006). Stromal-epithelial interaction in prostate cancer progression. Clinical Genitourinary Cancer, 5(2), 162–170. doi:10.3816/CGC.2006.n.034.PubMed

79.

Clezardin, P., & Teti, A. (2007). Bone metastasis: pathogenesis and therapeutic implications. Clinical and Experimental Metastasis, 24(8), 599–608. doi:10.1007/s10585-007-9112-8.PubMed

80.

Tsubochi, H., Endo, S., Oda, Y., & Dobashi, Y. (2013). Carcinoid tumor of the lung with massive ossification: report of a case showing the evidence of osteomimicry and review of the literature. International Journal of Clinical and Experimental Pathology, 6(5), 957–961.PubMedCentralPubMed

81.

Bhatia, M. (2010). Developmental biology. Microenvironment mimicry. Science, 329(5995), 1024–1025. doi:10.1126/science.1194919.PubMed

82.

Bissell, M. J. (1999). Tumor plasticity allows vasculogenic mimicry, a novel form of angiogenic switch. A rose by any other name? American Journal of Pathologists, 155(3), 675–679. doi:10.1016/S0002-9440(10)65164-4.

83.

Folberg, R., Hendrix, M. J., & Maniotis, A. J. (2000). Vasculogenic mimicry and tumor angiogenesis. The American Journal of Pathology, 156(2), 361–381. doi:10.1016/S0002-9440(10)64739-6.PubMedCentralPubMed

84.

Folberg, R., & Maniotis, A. J. (2004). Vasculogenic mimicry. APMIS, 112(7–8), 508–525. doi:10.1111/j.1600-0463.2004.apm11207-0810.x.PubMed

85.

Hendrix, M. J., Seftor, E. A., Hess, A. R., & Seftor, R. E. (2003). Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nature Reviews Cancer, 3(6), 411–421. doi:10.1038/nrc1092.PubMed

86.

McDonald, D. M., Munn, L., & Jain, R. K. (2000). Vasculogenic mimicry: how convincing, how novel, and how significant? The American Journal of Pathology, 156(2), 383–388. doi:10.1016/S0002-9440(10)64740-2.PubMedCentralPubMed

87.

Hugo, H., Ackland, M. L., Blick, T., Lawrence, M. G., Clements, J. A., Williams, E. D., et al. (2007). Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. Journal of Cellular Physiology, 213(2), 374–383. doi:10.1002/jcp.21223.PubMed

88.

Nauseef, J. T., & Henry, M. D. (2011). Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nature Reviews. Urology, 8(8), 428–439. doi:10.1038/nrurol.2011.85.PubMed

89.

van der Pluijm, G. (2011). Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone, 48(1), 37–43. doi:10.1016/j.bone.2010.07.023.PubMed

90.

Cogle, C. R., Theise, N. D., Fu, D., Ucar, D., Lee, S., Guthrie, S. M., et al. (2007). Bone marrow contributes to epithelial cancers in mice and humans as developmental mimicry. Stem Cells, 25(8), 1881–1887. doi:10.1634/stemcells.2007-0163.PubMed

91.

Ping, Y. F., & Bian, X. W. (2011). Consice review: Contribution of cancer stem cells to neovascularization. Stem Cells, 29(6), 888–894. doi:10.1002/stem.650.PubMed

92.

Timar, J., Tovari, J., Raso, E., Meszaros, L., Bereczky, B., & Lapis, K. (2005). Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. Oncology, 69(3), 185–201. doi:10.1159/000088069.PubMed

93.

Yao, X. H., Ping, Y. F., & Bian, X. W. (2011). Contribution of cancer stem cells to tumor vasculogenic mimicry. Protein & Cell, 2(4), 266–272. doi:10.1007/s13238-011-1041-2.

94.

Danza, G., Di Serio, C., Rosati, F., Lonetto, G., Sturli, N., Kacer, D., et al. (2012). Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. Molecular Cancer Research, 10(2), 230–238. doi:10.1158/1541-7786.MCR-11-0296.PubMedCentralPubMed

95.

Eisinger-Mathason, T. S., & Simon, M. C. (2010). HIF-1alpha partners with FoxA2, a neuroendocrine-specific transcription factor, to promote tumorigenesis. Cancer Cell, 18(1), 3–4. doi:10.1016/j.ccr.2010.06.007.PubMedCentralPubMed

96.

McKeithen, D., Graham, T., Chung, L. W., & Odero-Marah, V. (2010). Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate, 70(9), 982–992. doi:10.1002/pros.21132.PubMedCentralPubMed

97.

Spiotto, M. T., & Chung, T. D. (2000). STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate, 42(3), 186–195.PubMed

98.

Lang, S. H., Sharrard, R. M., Stark, M., Villette, J. M., & Maitland, N. J. (2001). Prostate epithelial cell lines form spheroids with evidence of glandular differentiation in three-dimensional Matrigel cultures. British Journal of Cancer, 85(4), 590–599. doi:10.1054/bjoc.2001.1967.PubMedCentralPubMed

99.

Lang, S. H., Stark, M., Collins, A., Paul, A. B., Stower, M. J., & Maitland, N. J. (2001). Experimental prostate epithelial morphogenesis in response to stroma and three-dimensional matrigel culture. Cell Growth and Differentiation, 12(12), 631–640.PubMed

100.

Winkenwerder, J. J., Palechek, P. L., Reece, J. S., Saarinen, M. A., Arnold, M. A., Cohen, M. B., et al. (2003). Evaluating prostate cancer cell culturing methods: a comparison of cell morphologies and metabolic activity. Oncology Reports, 10(4), 783–789.PubMed

101.

Baker, E. L., Bonnecaze, R. T., & Zaman, M. H. (2009). Extracellular matrix stiffness and architecture govern intracellular rheology in cancer. Biophysical Journal, 97(4), 1013–1021. doi:10.1016/j.bpj.2009.05.054.PubMedCentralPubMed

102.

Docheva, D., Padula, D., Schieker, M., & Clausen-Schaumann, H. (2010). Effect of collagen I and fibronectin on the adhesion, elasticity and cytoskeletal organization of prostate cancer cells. Biochemical and Biophysical Research Communications, 402(2), 361–366. doi:10.1016/j.bbrc.2010.10.034.PubMed

103.

He, H., Yang, X., Davidson, A. J., Wu, D., Marshall, F. F., Chung, L. W., et al. (2010). Progressive epithelial to mesenchymal transitions in ARCaP E prostate cancer cells during xenograft tumor formation and metastasis. Prostate, 70(5), 518–528. doi:10.1002/pros.21086.PubMedCentralPubMed

104.

Xu, J., Wang, R., Xie, Z. H., Odero-Marah, V., Pathak, S., Multani, A., et al. (2006). Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate, 66(15), 1664–1673. doi:10.1002/pros.20488.PubMed

105.

Rhee, H. W., Zhau, H. E., Pathak, S., Multani, A. S., Pennanen, S., Visakorpi, T., et al. (2001). Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel. In Vitro Cell Dev Biol Anim, 37(3), 127–140. doi:10.1290/1071-2690(2001)037<0127:PPAGCO>2.0.CO;2.PubMed

106.

Sung, S. Y., Hsieh, C. L., Law, A., Zhau, H. E., Pathak, S., Multani, A. S., et al. (2008). Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Research, 68(23), 9996–10003. doi:10.1158/0008-5472.CAN-08-2492.PubMedCentralPubMed

107.

Kaplun, A., Dzinic, S., Bernardo, M., & Sheng, S. (2012). Tumor suppressor maspin as a rheostat in HDAC regulation to achieve the fine-tuning of epithelial homeostasis. Critical Reviews in Eukaryotic Gene Expression, 22(3), 249–258.PubMedCentralPubMed

108.

Ruppender, N. S., Morrissey, C., Lange, P. H., & Vessella, R. L. (2013). Dormancy in solid tumors: implications for prostate cancer. Cancer and Metastasis Reviews. doi:10.1007/s10555-013-9422-z.PubMed

109.

Chauhan, S., & Tyagi, J. S. (2008). Interaction of DevR with multiple binding sites synergistically activates divergent transcription of narK2-Rv1738 genes in Mycobacterium tuberculosis. Journal of Bacteriology, 190(15), 5394–5403. doi:10.1128/JB.00488-08.PubMedCentralPubMed

110.

Vaistij, F. E., Gan, Y., Penfield, S., Gilday, A. D., Dave, A., He, Z., et al. (2013). Differential control of seed primary dormancy in Arabidopsis ecotypes by the transcription factor SPATULA. Proceedings of the National Academy of Sciences of the United States of America, 110(26), 10866–10871. doi:10.1073/pnas.1301647110.PubMedCentralPubMed

111.

Nadendla, S. K., Hazan, A., Ward, M., Harper, L. J., Moutasim, K., Bianchi, L. S., et al. (2011). GLI1 confers profound phenotypic changes upon LNCaP prostate cancer cells that include the acquisition of a hormone independent state. PLoS One, 6(5), e20271. doi:10.1371/journal.pone.0020271.PubMedCentralPubMed

112.

Shigemura, K., Huang, W. C., Li, X., Zhau, H. E., Zhu, G., Gotoh, A., et al. (2011). Active sonic hedgehog signaling between androgen independent human prostate cancer cells and normal/benign but not cancer-associated prostate stromal cells. Prostate, 71(16), 1711–1722. doi:10.1002/pros.21388.PubMedCentralPubMed

113.

Javelaud, D., Alexaki, V. I., Dennler, S., Mohammad, K. S., Guise, T. A., & Mauviel, A. (2011). TGF-beta/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Research, 71(17), 5606–5610. doi:10.1158/0008-5472.CAN-11-1194.PubMedCentralPubMed

114.

Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., et al. (2011). VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell, 20(6), 701–714. doi:10.1016/j.ccr.2011.11.002.PubMedCentralPubMed

115.

Shiozawa, Y., Pedersen, E. A., & Taichman, R. S. (2010). GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche. Experimental Hematology, 38(2), 132–140. doi:10.1016/j.exphem.2009.11.002.PubMedCentralPubMed

116.

Taichman, R. S., Patel, L. R., Bedenis, R., Wang, J., Weidner, S., Schumann, T., et al. (2013). GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS One, 8(4), e61873. doi:10.1371/journal.pone.0061873.PubMedCentralPubMed

117.

Lim, P. K., Bliss, S. A., Patel, S. A., Taborga, M., Dave, M. A., Gregory, L. A., et al. (2011). Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Research, 71(5), 1550–1560. doi:10.1158/0008-5472.CAN-10-2372.PubMed

118.

Almog, N., Briggs, C., Beheshti, A., Ma, L., Wilkie, K. P., Rietman, E., et al. (2013). Transcriptional changes induced by the tumor dormancy-associated microRNA-190. Transcription, 4(4).

119.

Almog, N., Ma, L., Schwager, C., Brinkmann, B. G., Beheshti, A., Vajkoczy, P., et al. (2012). Consensus micro RNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype. PLoS One, 7(8), e44001. doi:10.1371/journal.pone.0044001.PubMedCentralPubMed

120.

Bidard, F. C., Pierga, J. Y., Vincent-Salomon, A., & Poupon, M. F. (2008). A “class action” against the microenvironment: do cancer cells cooperate in metastasis? Cancer and Metastasis Reviews, 27(1), 5–10. doi:10.1007/s10555-007-9103-x.PubMedCentralPubMed

121.

Pathak, S., Nemeth, M. A., Multani, A. S., Thalmann, G. N., von Eschenbach, A. C., & Chung, L. W. (1997). Can cancer cells transform normal host cells into malignant cells? British Journal of Cancer, 76(9), 1134–1138.PubMedCentralPubMed

122.

Liu, Q., Russell, M. R., Shahriari, K., Jernigan, D. L., Lioni, M. I., Garcia, F. U., et al. (2013). Interleukin-1beta promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features. Cancer Research, 73(11), 3297–3305. doi:10.1158/0008-5472.CAN-12-3970.PubMed

123.

Giatromanolaki, A., Koukourakis, M. I., Koutsopoulos, A., Mendrinos, S., & Sivridis, E. (2012). The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biology and Therapy, 13(13), 1284–1289. doi:10.4161/cbt.21785.PubMedCentralPubMed

124.

Sotgia, F., Martinez-Outschoorn, U. E., Pavlides, S., Howell, A., Pestell, R. G., & Lisanti, M. P. (2011). Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Research, 13(4), 213. doi:10.1186/bcr2892.PubMedCentralPubMed

125.

Tumati, V., Kumar, S., Yu, L., Chen, B., Choy, H., & Saha, D. (2013). Effect of PF-02341066 and radiation on non-small cell lung cancer cells. Oncology Reports, 29(3), 1094–1100. doi:10.3892/or.2012.2198.PubMedCentralPubMed

126.

Pan, B. S., Chan, G. K., Chenard, M., Chi, A., Davis, L. J., Deshmukh, S. V., et al. (2010). MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Research, 70(4), 1524–1533. doi:10.1158/0008-5472.CAN-09-2541.PubMed

127.

Munshi, N., Jeay, S., Li, Y., Chen, C. R., France, D. S., Ashwell, M. A., et al. (2010). ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Molecular Cancer Therapeutics, 9(6), 1544–1553. doi:10.1158/1535-7163.MCT-09-1173.PubMed

128.

Yakes, F. M., Chen, J., Tan, J., Yamaguchi, K., Shi, Y., Yu, P., et al. (2011). Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Molecular Cancer Therapeutics, 10(12), 2298–2308. doi:10.1158/1535-7163.MCT-11-0264.PubMed

129.

Sen, B., Peng, S., Saigal, B., Williams, M. D., & Johnson, F. M. (2011). Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clinical Cancer Research, 17(3), 514–524. doi:10.1158/1078-0432.CCR-10-1617.PubMedCentralPubMed

130.

Harvey, S. R., Porrini, M., Stachl, C., MacMillan, D., Zinzalla, G., & Barran, P. E. (2012). Small-molecule inhibition of c-MYC:MAX leucine zipper formation is revealed by ion mobility mass spectrometry. Journal of the American Chemical Society, 134(47), 19384–19392. doi:10.1021/ja306519h.PubMed

131.

Kim, J., Roh, M., & Abdulkadir, S. A. (2010). Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer, 10, 248. doi:10.1186/1471-2407-10-248.PubMedCentralPubMed

132.

Carmody, L. C., Germain, A., Morgan, B., VerPlank, L., Fernandez, C., Feng, Y., et al. (2010). Identification of a Selective Small-Molecule Inhibitor of Breast Cancer Stem Cells - Probe 2. In Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD).

133.

Park, C. Y., Son, J. Y., Jin, C. H., Nam, J. S., Kim, D. K., & Sheen, Y. Y. (2011). EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. European Journal of Cancer, 47(17), 2642–2653. doi:10.1016/j.ejca.2011.07.007.PubMed

Title: RANK-mediated signaling network and cancer metastasis
Authors: Gina Chia-Yi Chu
Leland W. K. Chung
Publication date: 01-09-2014
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 2-3/2014
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-013-9488-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2-3/2014

Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy

Androgen receptor signaling in prostate cancer

Immunotherapy for prostate cancer: recent developments and future challenges

Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel

Emerging roles of radioresistance in prostate cancer metastasis and radiation therapy

Extracellular acidity, a “reappreciated” trait of tumor environment driving malignancy: perspectives in diagnosis and therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer